BRCA Genetic Testing Denied by Insurance? Your Rights and How to Appeal

BRCA1 and BRCA2 gene mutations dramatically increase the risk of breast and ovarian cancer. Women with these mutations face lifetime breast cancer risks of 50–85% and ovarian cancer risks of 25–46%. Early identification through genetic testing can save lives by enabling increased surveillance, risk-reducing surgery, and targeted prevention strategies.

Yet insurance companies regularly deny BRCA genetic testing — sometimes in clear violation of federal law. Here's what you need to know.

The ACA Preventive Coverage Mandate for BRCA Testing

The U.S. Preventive Services Task Force (USPSTF) gives a B recommendation to BRCA-related risk assessment and genetic counseling for women with a family history that indicates elevated risk for potentially harmful BRCA1/2 mutations. Under the ACA, all USPSTF A and B recommendations must be covered by non-grandfathered health plans at zero cost-sharing.

This means: if you have a qualifying family history, your BRCA genetic testing must be covered at no cost to you.

The USPSTF B recommendation covers the pathway of:

1. Risk assessment: Your provider evaluates your family history using a validated tool (e.g., B-RST, Ontario Family History Assessment Tool)
2. Genetic counseling: Referral to a genetic counselor if risk assessment is positive
3. BRCA genetic testing: If genetic counseling indicates testing is appropriate

Qualifying family history factors include (among others):

• First-degree relative (parent, sibling, child) with breast cancer before age 50
• First-degree relative with ovarian, fallopian tube, or primary peritoneal cancer at any age
• Two or more relatives on the same side of the family with breast cancer
• Any male relative with breast cancer
• Ashkenazi Jewish heritage with any first-degree relative with breast or ovarian cancer
• Known BRCA mutation in the family

If you meet any of these criteria, your insurer is legally required to cover genetic counseling and BRCA testing at no cost-share.

NCCN Hereditary Breast and Ovarian Cancer Syndrome Guidelines

The National Comprehensive Cancer Network (NCCN) publishes detailed guidelines for hereditary breast and ovarian cancer syndrome (HBOC). These guidelines specify who should be offered genetic testing and which genes should be tested.

The NCCN HBOC guidelines expand beyond the USPSTF criteria and are used by oncologists, genetic counselors, and specialists to guide clinical decision-making. For patients who don't meet the narrow USPSTF B recommendation criteria but who have significant family history, NCCN guidelines may support testing as medically necessary — even if it doesn't qualify as "preventive."

In your appeal, you may need to cite both the USPSTF B recommendation (for the preventive/no-cost-sharing argument) and the NCCN HBOC guidelines (for the medical necessity argument).

BRCA Testing Lab Options: Myriad Genetics and Beyond

For many years, Myriad Genetics held a patent monopoly on BRCA testing. Since the Supreme Court's 2013 ruling in Association for Molecular Pathology v. Myriad Genetics, multiple labs now offer BRCA testing — often at significantly lower cost.

Insurers may:

• Cover testing only at specific in-network labs
• Deny coverage at certain labs claiming they are out-of-network
• Require specific test versions (BRACAnalysis vs. multi-gene panels)

If your insurer denied BRCA testing at a specific lab:

• Check whether that lab is in-network
• If no in-network lab offers BRCA testing (unusual but possible), appeal for out-of-network coverage at in-network rates
• If a multi-gene panel was ordered (testing BRCA1/2 plus PALB2, ATM, CHEK2, etc.) and denied, your genetic counselor can document the clinical rationale for a broader panel

Common Denial Tactics and How to Counter Them

"Family history does not meet criteria"

If your insurer claims your family history doesn't qualify, review the USPSTF B recommendation criteria carefully. If you meet any of the listed criteria, file an appeal citing the specific criterion you satisfy.

"Genetic counseling must occur before testing"

This is actually consistent with the USPSTF pathway — counseling precedes testing. If your insurer denied the testing because counseling was not done first, schedule genetic counseling immediately and resubmit the authorization. If counseling itself was denied, that is a separate ACA violation to appeal.

"Testing is for diagnostic purposes, not preventive"

If you already have a breast or ovarian cancer diagnosis, your BRCA testing may be ordered diagnostically (to guide treatment decisions, such as whether PARP inhibitors are appropriate) rather than preventively. In this case, the testing is a diagnostic/treatment decision tool and should be covered as medically necessary — not preventive — care.

"Only testing for specific genes is covered"

If a multi-gene hereditary cancer panel was ordered and denied, appeal citing your genetic counselor's recommendation and the clinical rationale for the broader panel (e.g., personal or family history suggesting non-BRCA hereditary cancer syndromes).

Risk-Reducing Surgery After Positive BRCA Test

For BRCA1/2 carriers, risk-reducing bilateral salpingo-oophorectomy (RRSO) and consideration of risk-reducing mastectomy (RRM) are established preventive interventions. Insurance coverage for these surgical interventions in BRCA carriers should be covered as medically necessary procedures. If your risk-reducing surgery was denied, appeal citing NCCN HBOC guidelines and your confirmed BRCA mutation status.

How to Appeal a BRCA Testing Denial

Step 1: Document your qualifying family history. Prepare a family pedigree showing all relevant diagnoses, relationship to you, and age at diagnosis.

Step 2: Identify the USPSTF criteria met. Match your family history to specific USPSTF B recommendation criteria.

Step 3: Get a referral letter from your provider or genetic counselor. Documentation that you underwent risk assessment and the result was positive for elevated BRCA risk.

Step 4: File your appeal. Cite the USPSTF B recommendation and the ACA preventive services mandate (42 U.S.C. § 300gg-13). For medical necessity appeals, cite NCCN HBOC guidelines.

Step 5: Escalate to External Independent Review: Complete Guide" class="auto-link">external review. External reviewers with oncology or genetics expertise regularly uphold BRCA testing appeals.

Key Takeaways

• BRCA genetic testing for qualifying family histories is a USPSTF B-rated covered preventive service at no cost-share
• Multiple labs now offer BRCA testing since the Myriad patent was invalidated
• NCCN HBOC guidelines support broader testing criteria beyond the USPSTF pathway
• Risk-reducing surgery for confirmed BRCA carriers should be covered as medically necessary
• External review is highly effective for genetic testing denial appeals

Fight Back With ClaimBack

ClaimBack helps you identify whether your family history meets USPSTF criteria and builds an appeal letter citing the exact legal mandate your insurer is ignoring.

Start your free appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: What's the Difference?